Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
A pilot study was performed at The University of Texas M. D. Anderson Cancer Center to determine the feasibility of using thalidomide in a population of renal-cell carcinoma patients who had progressive disease despite chemotherapy and immunotherapy. Metastatic renal-cell carcinoma patients with adequate oral function were entered onto a study after signing an internal review board-approved informed consent. There were no exclusion criteria for prior therapy. Nineteen previously treated patients and one untreated patient with progressive renal-cell carcinoma received oral thalidomide as a single agent. The starting dose was 200 mg and the dose was increased by 100 to 200 mg every week until it reached 1,200 mg/d. Response was assessed on the basis of a radiographic reduction of the metastatic sites involved. A case report describing one of the patients involved in the pilot trial is included.
Amato
R
R
Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA.
D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000601:surgery; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D009362:Neoplasm Metastasis; D010865:Pilot Projects; D012008:Recurrence; D013792:Thalidomide / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D007376:Interleukin-2; D013792:Thalidomide; D005472:Fluorouracil